for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Meridian Bioscience, Inc.

VIVO.OQ

Latest Trade

15.46USD

Change

1.28(+9.03%)

Volume

477,782

Today's Range

14.58

 - 

15.53

52 Week Range

5.51

 - 

18.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.18
Open
15.15
Volume
477,782
3M AVG Volume
19.49
Today's High
15.53
Today's Low
14.58
52 Week High
18.58
52 Week Low
5.51
Shares Out (MIL)
42.83
Market Cap (MIL)
662.20
Forward P/E
20.89
Dividend (Yield %)
--

Latest Developments

More

Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products

Meridian Bioscience Announces Preliminary Q2 2020 Revenue Results

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results And Reaffirms 2020 Guidance

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Meridian Bioscience, Inc.

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Industry

Medical Equipment & Supplies

Contact Info

3471 River Hills Dr

CINCINNATI, OH

45244

United States

+1.513.2713700

http://www.meridianbioscience.com

Executive Leadership

David C. Phillips

Independent Chairman of the Board

John P. Kenny

Chief Executive Officer, Director

Bryan T. Baldasare

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer

Lourdes Weltzien

Executive Vice President - Life Science

James M. Anderson

Independent Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (USD)

2017

0.670

2018

0.740

2019

0.680

2020(E)

0.740
Price To Earnings (TTM)
31.06
Price To Sales (TTM)
3.25
Price To Book (MRQ)
3.24
Price To Cash Flow (TTM)
20.07
Total Debt To Equity (MRQ)
23.87
LT Debt To Equity (MRQ)
23.87
Return on Investment (TTM)
8.36
Return on Equity (TTM)
7.46

Latest News

Latest News

BRIEF-Meridian To Supply Reagents To Make Tens Of Millions Of COVID-19 Antibody Tests Per Month

* MERIDIAN BIOSCIENCE ANNOUNCES IT WILL SUPPLY REAGENTS FOR MANUFACTURING OF TENS OF MILLIONS OF COVID-19 ANTIBODY TESTS PER MONTH Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products

* MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS

BRIEF-Meridian Bioscience Partners With QuantuMDx On COVID-19 Assay

* MERIDIAN BIOSCIENCE PARTNERS WITH QUANTUMDX ON COVID-19 ASSAY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

* MERIDIAN BIOSCIENCE INC - ANNOUNCED LAUNCH OF SEVERAL NOVEL RECOMBINANT ANTIGENS FOR DEVELOPMENT OF ANTIBODY TESTS FOR COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Announces Preliminary Q2 2020 Revenue Results

* MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

BRIEF-Meridian Bioscience Is Making Available Zero Cost Samples Of Molecular Assays For Covid-19 Detection

* MERIDIAN BIOSCIENCE - MAKING AVAILABLE ZERO COST SAMPLES OF TECHNOLOGIES TO DEVELOPERS & MANUFACTURERS OF MOLECULAR ASSAYS FOR COVID-19 DETECTION Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Announces FDA-Clearance For New Curian Analyzer And The Curian HPSA Assay

* MERIDIAN BIOSCIENCE ANNOUNCES FDA-CLEARANCE FOR NEW CURIAN™ ANALYZER AND THE CURIAN™ HPSA® ASSAY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results And Reaffirms 2020 Guidance

* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER FISCAL 2020 OPERATING RESULTS AND REAFFIRMS 2020 GUIDANCE

FDA approves Meridian Bioscience's test for herpes in newborns

The U.S. Food and Drug Administration approved on Friday the first test - a diagnostic from Meridian Bioscience Inc - to help detect a type of herpes virus in newborns.

FDA approves Meridian Bioscience's diagnostic for herpes in newborns

The U.S. Food and Drug Administration approved on Friday a diagnostic test from Meridian Bioscience Inc as the first tool to help detect a type of herpes virus in newborns.

BRIEF-Meridian Bioscience Reports Q2 GAAP EPS Of $0.12

* MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR SECOND QUARTER CASH DIVIDEND, AND UPDATES FISCAL 2018 GUIDANCE

BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15

* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE

BRIEF-Co-Diagnostics Announces Sale Of Molecular Diagnostic Tests

* CO-DIAGNOSTICS, INC. ANNOUNCES SALE OF MOLECULAR DIAGNOSTIC TESTS, INCLUDING ZIKA VIRUS, TO MAJOR CARIBBEAN LABORATORY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Files For Mixed Shelf Of Up To $100 Million

* MERIDIAN BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: (http://bit.ly/2k7rdVf) Further company coverage:

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary

FDA warns Meridian of violations for lead-testing devices

The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

BRIEF-MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO

* MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up